Bardy Diagnostics™ Announces $35.5M in Series B Funding Round

心脏监测技术供应商Bardy Diagnostics获3550万美元B轮融资

2019-04-17 10:56:00 BioSpace

本文共1316个字,阅读需4分钟

Bardy Diagnostics, Inc.  , a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has raised $35.5 million in Series B funding, led by River Cities Capital Funds with participation from new investors HealthQuest Capital, Aperture Venture Partners, Aphelion Capital, Lumira Ventures, and Rex Health Ventures. Existing equity investors, SV Health Investors, Health Enterprise Partners, and Ascension Ventures also joined the round. The funds will be used to further accelerate growth of its innovative P-wave focused cardiac monitoring platform through expansion of BardyDx's sales force and monitoring services, and to support advanced development programs, including augmented intelligence and visualization technologies. "The caliber of our new investors in addition to our exceptional existing syndicate of financiers underscores the exciting opportunity before us," said Gust H. Bardy, MD, Founder and Chief Executive Officer of BardyDx. "With these funds, we will grow our business by refining and expanding our primary goal of revealing to patients, and their physicians, the full complexity and meaning of their cardiac rhythm."  BardyDx's Carnation Ambulatory Monitor ("CAM™") is the industry's only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device. The genesis of the CAM is a result of Dr. Bardy's frustrations with the fundamental flaws rooted in the development and evolution of cardiac monitoring. "For nearly 60 years, standard ECG engineering practices have over-processed the heart's electrical message to make machines' 'lives' easier at the expense of losing details in the ECG," added Dr. Bardy. "In essence, such legacy engineering doesn't listen to what the heart is trying to tell us but rather tells the heart what we are willing to hear. At BardyDx, our pioneering technology focuses on revealing the cardiac rhythm message fully, and in so doing, allows for precise and meaningful patient management predicated on cardiac truth."  BardyDx's footprint within the cardiac monitoring industry continues to expand with growing recognition of the innovative P-wave centric technology. The company was recently selected winner of the Impact Pediatric Health Competition at SXSW, Children's National Health System Pediatric Medical Device Innovation Competition, and 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation. "Our Series B capital will continue to fuel the technological innovation that Dr. Bardy has always insisted on and for which BardyDx has come to be known," said Mark Handfelt, BardyDx's Chief Operating Officer. BardyDx also announced that Rik Vandevenne, Managing Director of River Cities Capital Funds, and Garheng Kong, Managing Director of HealthQuest Capital, will join the company's board of directors. "It's not every day you have the opportunity to partner with such a groundbreaking serial entrepreneur and innovator as Dr. Gust Bardy and the team at BardyDx," said Vandevenne. "The company has a clear focus on putting the patient first and they have developed a clinically-superior ECG platform that is revolutionizing heart monitoring. We are excited for the opportunity to help further drive growth for the company while positively impacting the lives of thousands of people every week."
Bardy Diagnostics , Inc .是一家领先的非卧床心脏监测技术和定制数据解决方案提供商。该公司今天宣布,已经筹集了3550万美元的 B 系列资金,其中由 River Cities Capital Funds 牵头,新投资者 HealthQuest Capital 、 Aperture Venture Partners 、 Aphelon Capital 、 Lumira VenturesRex Health Ventures 。现有股权投资者、 SV Health Investors 、 Health Enterprise Partners 和 Ascension Ventures 也加入了本轮融资。这些资金将用于通过扩大 BardyDx 的销售队伍和监测服务,进一步加快其以 P 波为中心的创新心脏监测平台的增长,并支持包括增强智能和可视化技术在内的先进开发计划。 BardyDx 创始人兼首席执行官 Gust H . Bardy 医学博士说:“除了我们现有的特殊融资财团外,我们新投资者的才干突显了我们面前的激动人心的机遇。”“有了这些资金,我们将通过完善和扩大我们的首要目标来发展我们的业务,向患者和他们的医生展示他们心脏节律的全部复杂性和意义。”这是一个很好的例子 BardyDx 的 Carnational Ambulary Monitor (" CAM ™)是业界唯一的 P 波中心™动态心脏贴片监视器和心律失常检测设备。CAM 的起源是 Bardy 博士对心脏监测发展和演变中的根本缺陷感到沮丧的结果。 “近60年来,标准的心电图工程实践已经过多地处理心脏的电子信息,使机器的“生活”更容易,而在心电图中丢失细节,”巴迪博士补充说。“从本质上讲,这样的遗留工程并不听内心想告诉我们什么,而是告诉我们内心我们愿意听到什么。在 BardyDx ,我们的开创性技术侧重于充分揭示心脏节律信息,这样做,允许基于心脏真相的精确和有意义的病人管理。”这是一个很好的例子 随着人们越来越认识到以 P 波为中心的创新技术, BardyDx 在心脏监测行业的足迹继续扩大。公司于近日入选 SXSW 《影响儿科健康竞赛》、《儿童国家卫生系统儿科医疗器械创新大赛》、《2018年医疗器械创新领域创新生命科学奖》。“我们的 B 系列资本将继续推动 Bardy 博士一直坚持的技术创新, BardyDx 已经为此而闻名,” BardyDx 首席运营官 Mark Handsfect 说。 BardyDx 还宣布, RiverCities Capital Funds 董事总经理 Rik Vandevenne 和 HealthQuest Capital 董事总经理 Garheng Kong 将加入该公司董事会。 “这并不是每天都有机会与如此开创性的企业家和创新者合作,如古斯特·巴迪博士和 BardyDx 的团队,” Vandevenne 说。“该公司明确地把重点放在病人的第一,他们已经开发了一个临床上优越的心电平台,这是革命性的心脏监测。我们很高兴有机会帮助公司进一步推动增长,同时积极影响每周成千上万人的生活。”

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文